TY - JOUR
T1 - Combination of novel systemic agents and radiotherapy for solid tumors – part I
T2 - An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy
AU - Arcangeli, Stefano
AU - Jereczek-Fossa, Barbara Alicia
AU - Alongi, Filippo
AU - Aristei, Cynthia
AU - Becherini, Carlotta
AU - Belgioia, Liliana
AU - Buglione, Michela
AU - Caravatta, Luciana
AU - D'Angelillo, Rolando Maria
AU - Filippi, Andrea Riccardo
AU - Fiore, Michele
AU - Genovesi, Domenico
AU - Greco, Carlo
AU - Livi, Lorenzo
AU - Magrini, Stefano Maria
AU - Marvaso, Giulia
AU - Mazzola, Rosario
AU - Meattini, Icro
AU - Merlotti, Anna
AU - Palumbo, Isabella
AU - Pergolizzi, Stefano
AU - Ramella, Sara
AU - Ricardi, Umberto
AU - Russi, Elvio
AU - Trovò, Marco
AU - Sindoni, Alessandro
AU - Valentini, Vincenzo
AU - Corvò, Renzo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.
AB - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85059913505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059913505&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2018.11.005
DO - 10.1016/j.critrevonc.2018.11.005
M3 - Article
AN - SCOPUS:85059913505
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -